Description
Tirzepatide is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly and studied under the brand names Mounjaro and Zepbound. It is investigated for its potential to improve glycemic control and support weight management by targeting two incretin pathways. Tirzepatide is a subject of ongoing research in metabolic and endocrine studies. Provided as a lyophilized powder for research purposes only.
Reviews
There are no reviews yet.